Around 200 million people worldwide have some form of thyroid disease. Worldwide, it is estimated that 1 billion people are at risk of developing a thyroid goiter. Statistically, women are 5 to 8 times more likely than men to develop some form of thyroid disease.

Along with the traditional and consolidated first line assays for assessing the thyroid function (FT4, TSH) DiaSorin offers the opportunity to further investigate thyroid diseases with FT3 assays and an assay for the measurement of autoantibodies to Thyroid Peroxidase (TPO).

DiaSorin offers tests for many of the major Thyroid markers for diagnosis, follow-up and monitoring of treatment of thyroid diseases using either RIA technology or the LIAISON® systems.